The Centers for Medicare & Medicaid Services May 16 released a final rule with the intent of lowering drug prices for beneficiaries enrolled in Medicare Advantage and Part D programs. The rule finalizes language aimed at increasing transparency for Part D beneficiaries, as well as the option for MA plans to utilize step therapy for Part B drugs.
 

Related News Articles

Headline
People enrolled in Medicare Advantage are more likely than those in traditional Medicare to report delays in care due to needed insurance approvals, according…
Headline
Andrea Preisler, AHA’s senior associate director of administrative simplification policy, explains why the recent final rule requiring Medicare Advantage,…
Headline
The Centers for Medicare & Medicaid Services yesterday released FAQs clarifying coverage criteria and utilization management requirements for Medicare…
Headline
The Centers for Medicare & Medicaid Services will accept comments through March 1 at 6 p.m. ET on its advance notice of proposed changes to Medicare…
Headline
Chris Barber, president and CEO of St. Bernards Healthcare, discusses the problems certain MA plan practices can create for patients and their caregivers,…
Headline
In a statement submitted to the House Energy and Commerce Subcommittee on Health for a hearing Jan. 31 on national health expenditures, AHA urged the…